LIVIVO - Search results -

Search results

Result 1 - 10 of total 44

Search options

Article ; Online: SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients.

Chen, Yuxin / Zhao, Tiantian / Chen, Lin / Jiang, Guozhi / Geng, Yu / Li, Wanting / Yin, Shengxia / Tong, Xin / Tao, Yue / Ni, Jun / Lu, Qiuhan / Ning, Mingzhe / Wu, Chao

mBio

2024 Volume 15, Issue 4, Page(s) e0240723

Abstract: The inactivated whole-virion vaccine, CoronaVac, is one of the most widely used coronavirus disease 2019 (COVID-19) vaccines worldwide. There is a paucity of data indicating the durability of the immune response and the impact of immune imprinting ... ...

Abstract	The inactivated whole-virion vaccine, CoronaVac, is one of the most widely used coronavirus disease 2019 (COVID-19) vaccines worldwide. There is a paucity of data indicating the durability of the immune response and the impact of immune imprinting induced by CoronaVac upon Omicron infection. In this prospective cohort study, 41 recipients of triple-dose CoronaVac and 14 unvaccinated individuals were recruited. We comprehensively profiled adaptive immune parameters in both groups, including spike-specific immunoglobulin (Ig) G and IgA titers, neutralizing activity, B cells, circulating follicular helper T (cTfh) cells, CD4 Importance: There is a paucity of data indicating the durability of the immune response and the impact of immune imprinting induced by CoronaVac upon Omicron breakthrough infection. In this prospective cohort study, the anti-severe acute respiratory syndrome coronavirus 2 adaptive responses were analyzed before and after the Omicron BA.5 infection. Our data provide detailed insight into the protective role of the inactivated COVID-19 vaccine in shaping humoral and cellular immune responses to heterologous Omicron infection. Clinical trial: This study is registered with ClinicalTrials.gov as NCT05680896.
MeSH term(s)	Humans ; Immunity, Mucosal ; COVID-19 Vaccines ; COVID-19 ; SARS-CoV-2 ; Breakthrough Infections ; CD8-Positive T-Lymphocytes ; Prospective Studies ; Immunoglobulin G ; Immunoglobulin A ; Antibodies, Viral ; Antibodies, Neutralizing ; Vaccines, Inactivated
Chemical Substances	sinovac COVID-19 vaccine ; COVID-19 Vaccines ; Immunoglobulin G ; Immunoglobulin A ; Antibodies, Viral ; Antibodies, Neutralizing ; Vaccines, Inactivated
Language	English
Publishing date	2024-03-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	2557172-2
ISSN	2150-7511 ; 2161-2129
ISSN (online)	2150-7511
ISSN	2161-2129
DOI	10.1128/mbio.02407-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes.

Ma, Xiaoyan / Zhu, Yixuan / Yeo, Yee Hui / Fan, Zhiwen / Xu, Xiaoming / Rui, Fajuan / Ni, Wenjing / Gu, Qi / Tong, Xin / Yin, Shengxia / Qi, Xiaolong / Shi, Junping / Wu, Chao / Li, Jie

Hepatology international

2024

Abstract: Background and aims: Data on the effects of liver fibrosis and hepatic steatosis on outcomes in individuals living with diabetes are limited. Therefore, we investigated the predictive value of the fibrosis and the severity of hepatic steatosis for all- ... ...

Abstract	Background and aims: Data on the effects of liver fibrosis and hepatic steatosis on outcomes in individuals living with diabetes are limited. Therefore, we investigated the predictive value of the fibrosis and the severity of hepatic steatosis for all-cause mortality in individuals living with diabetes. Methods: A total of 1903 patients with diabetes from the Third National Health and Nutrition Examination Survey (NHANES III) dataset were enrolled. Presumed hepatic fibrosis was evaluated with Fibrosis-4 index (FIB-4). The mortality risk and corresponding hazard ratio (HR) were analyzed with the Kaplan-Meier method and multivariable Cox proportional hazard models. Results: Over a median follow-up of 19.4 years, all-cause deaths occurred in 69.6%. FIB-4 ≥ 1.3 was an independent predictor of mortality in individuals living with diabetes (HR 1.219, 95% confidence interval [CI]: 1.067-1.392, p = 0.004). Overall, FIB-4 ≥ 1.3 without moderate-severe steatosis increased the mortality risk (HR 1.365; 95%CI 1.147-1.623, p < 0.001). The similar results were found in individuals living with diabetes with metabolic dysfunction-associated fatty liver disease (MAFLD) (HR 1.499; 95%CI 1.065-2.110, p = 0.020), metabolic syndrome (MetS) (HR 1.397; 95%CI 1.086-1.796, p = 0.009) or abdominal obesity (HR 1.370; 95%CI 1.077-1.742, p = 0.010). Conclusions: Liver fibrosis, as estimated by FIB-4, may serve as a more reliable prognostic indicator for individuals living with diabetes than hepatic steatosis. Individuals living with diabetes with FIB-4 ≥ 1.3 without moderate-severe steatosis had a significantly increased all-cause mortality risk. These findings highlight the importance of identifying and monitoring those individuals, as they may benefit from further evaluation and risk stratification.
Language	English
Publishing date	2024-01-22
Publishing country	United States
Document type	Journal Article
ZDB-ID	2270316-0
ISSN	1936-0541 ; 1936-0533
ISSN (online)	1936-0541
ISSN	1936-0533
DOI	10.1007/s12072-023-10625-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Serum CXCL16: A new predictor of liver inflammation in patients with chronic hepatitis B.

Wan, Yawen / Mao, Minxin / Li, Ming / Liu, Jiacheng / Tong, Xin / Wang, Jian / Li, Jie / Yin, Shengxia / Wu, Chao

Journal of viral hepatitis

2023 Volume 31, Issue 2, Page(s) 107–119

Abstract: The prompt initiation of antiviral therapy is essential in patients with chronic hepatitis B (CHB), especially when severe liver inflammation is detected. However, transcutaneous liver puncture, the gold standard for assessing liver inflammation, is ... ...

Abstract	The prompt initiation of antiviral therapy is essential in patients with chronic hepatitis B (CHB), especially when severe liver inflammation is detected. However, transcutaneous liver puncture, the gold standard for assessing liver inflammation, is invasive and its widespread application is limited. Therefore, there is an urgent need for more non-invasive markers to predict liver inflammation. In our retrospective cross-sectional study, which included 120 CHB patients and 31 healthy subjects, we observed a significant increase in serum chemokine C-X-C-motif ligand 16 (CXCL16) in CHB patients compared to healthy controls (p < .001). Notably, patients with severe inflammation (Scheuer's grade G ≥ 3, n = 26) exhibited a substantial increase in serum CXCL16 compared to those with non-severe inflammation (Scheuer's grade G < 3, n = 96) [(median, IQR), 0.42 (0.24-0.71) ng/mL vs. 1.01 (0.25-2.09) ng/mL, p < .001]. Furthermore, we developed a predictive model that combined CXCL16 with platelet count (PLT), alanine aminotransferase (ALT) and albumin (ALB) to accurately predict liver inflammation in CHB patients. This model was more effective than ALT alone in predicting liver inflammation (AUC, 0.92 vs. 0.81, p = .015). Additionally, using an HBV-transduced mouse model, we demonstrated that blocking CXCL16 led to a reduction in liver inflammation and impaired infiltration and function of natural killer T (NKT) and natural killer (NK) cells. These findings suggest that CXCL16 is a promising non-invasive biomarker of liver inflammation in CHB patients and may play a role in inducing liver inflammation via a NKT and NK cell pathway.
MeSH term(s)	Animals ; Mice ; Humans ; Hepatitis B, Chronic/complications ; Retrospective Studies ; Cross-Sectional Studies ; Hepatitis ; Hepatitis B virus ; Inflammation ; Hepatitis B e Antigens ; Chemokine CXCL16
Chemical Substances	Hepatitis B e Antigens ; CXCL16 protein, human ; Chemokine CXCL16
Language	English
Publishing date	2023-12-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1212497-7
ISSN	1365-2893 ; 1352-0504
ISSN (online)	1365-2893
ISSN	1352-0504
DOI	10.1111/jvh.13905
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4119: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study.

Yao, Renling / Lu, Sufang / Xue, Ruifei / Wang, Jian / Qiu, Yuanwang / Chen, Yuxin / Liu, Jiacheng / Zhu, Li / Zhan, Jie / Jiang, Suling / Yin, Shengxia / Tong, Xin / Ding, Weimao / Li, Jie / Zhu, Chuanwu / Huang, Rui / Wu, Chao

Annals of hepatology

2023 Volume 29, Issue 1, Page(s) 101155

MeSH term(s)	Humans ; Hepatitis B/complications ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/epidemiology ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/complications ; Non-alcoholic Fatty Liver Disease/diagnosis ; Non-alcoholic Fatty Liver Disease/epidemiology ; Non-alcoholic Fatty Liver Disease/complications ; Retrospective Studies
Language	English
Publishing date	2023-09-24
Publishing country	Mexico
Document type	Clinical Study ; Journal Article ; Multicenter Study
ZDB-ID	2188733-0
ISSN	1665-2681
ISSN	1665-2681
DOI	10.1016/j.aohep.2023.101155
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6221: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease.

Tong, Xin / Song, Yu / Yin, Shengxia / Wang, Jian / Huang, Rui / Wu, Chao / Shi, Junping / Li, Jie

Chinese medical journal

2022 Volume 135, Issue 14, Page(s) 1653–1663

Abstract: Abstract: Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the administration of vaccines and the use of antiviral treatments. In recent years, as the prevalence of obesity and metabolic syndrome has increased, ... ...

Abstract	Abstract: Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the administration of vaccines and the use of antiviral treatments. In recent years, as the prevalence of obesity and metabolic syndrome has increased, non-alcoholic fatty liver disease (NAFLD) in patients with CHB has become more common. Both diseases can lead to liver fibrosis and even hepatocellular carcinoma, but the risk of dual etiology, outcome, and CHB combined with NAFLD is not fully elucidated. In this review, we assess the overlapping prevalence of NAFLD and CHB, summarize recent studies of clinical and basic research related to potential interactions, and evaluate the progressive changes of treatments for CHB patients with NAFLD. This review increases the understanding of the relationship and mechanisms of interaction between steatosis and hepatitis B virus infection, and it provides new strategies for the future clinical management and treatment of CHB combined with NAFLD.
MeSH term(s)	Antiviral Agents/therapeutic use ; Hepatitis B virus ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/drug therapy ; Humans ; Liver Neoplasms/complications ; Non-alcoholic Fatty Liver Disease/drug therapy
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2022-07-20
Publishing country	China
Document type	Journal Article ; Review
ZDB-ID	127089-8
ISSN	2542-5641 ; 0366-6999 ; 1002-0187
ISSN (online)	2542-5641
ISSN	0366-6999 ; 1002-0187
DOI	10.1097/CM9.0000000000002310
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1207: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Ua VI Zs.425: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: miR-409-3p Regulated by GATA2 Promotes Cardiac Fibrosis through Targeting Gpd1.

Wang, Chun / Yin, Shengxia / Wang, Qin / Jiang, Min / Li, Shanshan / Zhen, Wen / Duan, Yi / Gu, Huanyu

Oxidative medicine and cellular longevity

2022 Volume 2022, Page(s) 8922246

Abstract: Cardiac fibrosis is a hallmark of numerous chronic cardiovascular diseases that leads to heart failure. However, there is no validated therapy for it. Dysregulation of microRNAs has been confirmed to be involved in cardiac fibrosis development. However, ... ...

Abstract	Cardiac fibrosis is a hallmark of numerous chronic cardiovascular diseases that leads to heart failure. However, there is no validated therapy for it. Dysregulation of microRNAs has been confirmed to be involved in cardiac fibrosis development. However, the regulatory network was not well explored. This study was the first to highlight the role and molecular mechanism of miR-409-3p in cardiac fibrosis. We found that miR-409-3p was consistently increased in three fibrotic models, including heart tissues of postmyocardial infarction (MI) mice and neonatal rat cardiac fibroblasts treated with angiotensin II (Ang II) or transforming growth factor-
MeSH term(s)	Mice ; Rats ; Animals ; Antagomirs/metabolism ; RNA, Small Interfering/metabolism ; Angiotensin II/metabolism ; Myocardium/pathology ; Fibrosis ; MicroRNAs/metabolism ; Myocardial Infarction/pathology ; Transforming Growth Factor beta/metabolism ; Transforming Growth Factors/metabolism ; Transcription Factors/metabolism ; GATA2 Transcription Factor/metabolism
Chemical Substances	Antagomirs ; RNA, Small Interfering ; Angiotensin II (11128-99-7) ; MicroRNAs ; Transforming Growth Factor beta ; Transforming Growth Factors (76057-06-2) ; Transcription Factors ; Gata2 protein, mouse ; GATA2 Transcription Factor
Language	English
Publishing date	2022-10-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	2455981-7
ISSN	1942-0994 ; 1942-0994
ISSN (online)	1942-0994
ISSN	1942-0994
DOI	10.1155/2022/8922246
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment.

Yin, Shengxia / Wan, Yawen / Issa, Rahma / Zhu, Yijia / Xu, Xiaoming / Liu, Jiacheng / Mao, Minxin / Li, Ming / Tong, Xin / Tian, Chen / Wang, Jian / Huang, Rui / Zhang, Qun / Wu, Chao / Chen, Yuxin / Li, Jie

Emerging microbes & infections

2023 Volume 12, Issue 2, Page(s) 2259003

Abstract: Indices for predicting HBsAg or HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection during antiviral therapy remain elusive. We aimed to investigate if the presence of HBsAb-specific B cells at baseline can predict HBsAg or ... ...

Abstract	Indices for predicting HBsAg or HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection during antiviral therapy remain elusive. We aimed to investigate if the presence of HBsAb-specific B cells at baseline can predict HBsAg or HBeAg seroconversion. In this study, 134 treatment-naive patients with chronic HBV were enrolled. A baseline HBsAb-specific B cell ELISpot assay was performed for all the patients that enrolled. Serum samples were collected at 12, 24, and 48 weeks for patients treated with Peg-IFN-α, or at 1 year, 3 years, and 5 years for patients treated with NAs. Laboratory testing of HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, HBV DNA, ALT, and AST was done. We observed a significantly lower frequency of HBsAb-specific B cells in patients with chronic HBV than in healthy individuals . In the Peg-IFN-α-treated group, 41.2% of patients with baseline HBsAb-specific B cells achieved HBsAg seroconversion, while only 13.6% of patients without baseline HBsAb-specific B cells achieved HBsAg seroconversion (
MeSH term(s)	Humans ; Hepatitis B, Chronic ; Antiviral Agents/therapeutic use ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Seroconversion ; Treatment Outcome ; DNA, Viral ; Interferon-alpha/therapeutic use ; Hepatitis B Antibodies ; Recombinant Proteins/therapeutic use
Chemical Substances	Antiviral Agents ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; DNA, Viral ; Interferon-alpha ; Hepatitis B Antibodies ; Recombinant Proteins
Language	English
Publishing date	2023-09-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	2681359-2
ISSN	2222-1751 ; 2222-1751
ISSN (online)	2222-1751
ISSN	2222-1751
DOI	10.1080/22221751.2023.2259003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Circulating Th2-biased T follicular helper cells impede antiviral humoral responses during chronic hepatitis B infection through upregulating CTLA4.

Yin, Shengxia / Wang, Jian / Chen, Lin / Mao, Minxin / Issa, Rahma / Geng, Yu / Huang, Rui / Tong, Xin / Liu, Yong / Wu, Chao / Chen, Yuxin / Li, Jie

Antiviral research

2023 Volume 216, Page(s) 105665

Abstract: Failure in curing chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) can lead to functional impairment of B cells. Cytotoxic T-lymphocyte associated antigen 4 (CTLA4) regulates B cell and T follicular helper (Tfh) cell differentiation. In ... ...

Abstract	Failure in curing chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) can lead to functional impairment of B cells. Cytotoxic T-lymphocyte associated antigen 4 (CTLA4) regulates B cell and T follicular helper (Tfh) cell differentiation. In addition, Tfh cells play a critical role in helping B cells generate antibodies upon pathogen exposure. Here, we analyzed the global and HBsAg-specific B cells and circulating Tfh (cTfh) cells using samples from treatment-naïve and Peg-IFN-α-treated CHB patients and healthy subjects. Compared to healthy subjects, CTLA4 expression was significantly increased in cTfh cells, from CHB patients. The frequency of CTLA4
MeSH term(s)	Humans ; T Follicular Helper Cells ; Hepatitis B Surface Antigens ; Hepatitis B, Chronic ; T-Lymphocytes, Helper-Inducer ; CTLA-4 Antigen/therapeutic use ; Hepatitis B/drug therapy ; Antiviral Agents/therapeutic use ; Antiviral Agents/pharmacology
Chemical Substances	Hepatitis B Surface Antigens ; CTLA-4 Antigen ; Antiviral Agents ; CTLA4 protein, human
Language	English
Publishing date	2023-07-07
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	306628-9
ISSN	1872-9096 ; 0166-3542
ISSN (online)	1872-9096
ISSN	0166-3542
DOI	10.1016/j.antiviral.2023.105665
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1627: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.

Wang, Jian / Zhu, Li / Zhang, Shaoqiu / Zhang, Zhiyi / Fan, Tao / Cao, Fei / Xiong, Ye / Pan, Yifan / Li, Yuanyuan / Jiang, Chao / Yin, Shengxia / Tong, Xin / Xiong, Yali / Xia, Juan / Yan, Xiaomin / Liu, Yong / Liu, Xingxiang / Chen, Yuxin / Li, Jie /

Zhu, Chuanwu / Wu, Chao / Huang, Rui

Emerging microbes & infections

2024 Volume 13, Issue 1, Page(s) 2339944

Abstract: Serum hepatitis B surface antigen (HBsAg) level < 100 IU/ml and undetectable hepatitis B virus (HBV) DNA have been recently proposed as an alternate endpoint of "partial cure" in chronic hepatitis B (CHB). We investigated clinical outcomes of hepatitis B ...

Abstract	Serum hepatitis B surface antigen (HBsAg) level < 100 IU/ml and undetectable hepatitis B virus (HBV) DNA have been recently proposed as an alternate endpoint of "partial cure" in chronic hepatitis B (CHB). We investigated clinical outcomes of hepatitis B e antigen (HBeAg)-negative CHB patients with HBsAg <100 IU/ml and undetectable HBV DNA. Treatment-naïve HBeAg-negative CHB patients with undetectable HBV DNA and normal alanine aminotransferase were retrospectively included from three institutions. Patients were classified into the low HBsAg group (<100 IU/ml) and the high HBsAg group (≥100 IU/ml). Liver fibrosis was evaluated by noninvasive tests (NITs). A total of 1218 patients were included and the median age was 41.5 years. Patients with low HBsAg were older (45.0 vs. 40.0 years,
MeSH term(s)	Humans ; Adult ; Hepatitis B Surface Antigens ; Hepatitis B, Chronic ; Hepatitis B e Antigens ; DNA, Viral ; Retrospective Studies ; Carcinoma, Hepatocellular ; Liver Neoplasms ; Hepatitis B virus/genetics ; Liver Cirrhosis ; Treatment Outcome ; Antiviral Agents/therapeutic use
Chemical Substances	Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; DNA, Viral ; Antiviral Agents
Language	English
Publishing date	2024-04-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	2681359-2
ISSN	2222-1751 ; 2222-1751
ISSN (online)	2222-1751
ISSN	2222-1751
DOI	10.1080/22221751.2024.2339944
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD.

Wang, Jian / Huang, Rui / Liu, Jiacheng / Lai, Ruimin / Liu, Yilin / Zhu, Chuanwu / Qiu, Yuanwang / He, Zebao / Yin, Shengxia / Chen, Yuxin / Yan, Xiaomin / Ding, Weimao / Zheng, Qi / Li, Jie / Wu, Chao

Journal of viral hepatitis

2023 Volume 30, Issue 4, Page(s) 287–296

Abstract: There are still lack of non-invasive models to evaluate liver fibrosis in chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD). We aimed to establish a predictive model for advanced fibrosis in these patients. A total of 504 ... ...

Abstract	There are still lack of non-invasive models to evaluate liver fibrosis in chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD). We aimed to establish a predictive model for advanced fibrosis in these patients. A total of 504 treatment-naive CHB patients with NAFLD who underwent liver biopsy were enrolled and randomly divided into a training set (n = 336) and a validation set (n = 168). Receiver operating characteristic (ROC) curve was used to compare predicting accuracy for the different models. One hundred fifty-six patients (31.0%) had advanced fibrosis. In the training set, platelet, prothrombin time, type 2 diabetes, HBeAg positivity and globulin were significantly associated with advanced fibrosis by multivariable analysis. A predictive model namely PPDHG for advanced fibrosis was developed based on these parameters. The areas under the ROC curve (AUROC) of PPDHG with an optimal cut-off value of -0.980 in predicting advanced fibrosis was 0.817 (95% confidence interval 0.772 to 0.862), with a sensitivity of 81.82% and a specificity of 66.81%. The predicting accuracy of PPDHG for advanced fibrosis was significantly superior to AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4) and NAFLD fibrosis score (NFS). Further analysis revealed that the AUROC of PPDHG remained significantly higher than FIB-4 and NFS indexes, while it was comparable with APRI for predicting advanced fibrosis in the validation set. PPDHG had a better predicting performance than established models for advanced fibrosis in CHB patients with NAFLD. The application of PPDHG can reduce the necessary for liver biopsy in these patients.
MeSH term(s)	Humans ; Non-alcoholic Fatty Liver Disease/pathology ; Hepatitis B, Chronic/complications ; Diabetes Mellitus, Type 2 ; Predictive Value of Tests ; Platelet Count ; Liver Cirrhosis/complications ; ROC Curve ; Biopsy ; Aspartate Aminotransferases ; Biomarkers
Chemical Substances	Aspartate Aminotransferases (EC 2.6.1.1) ; Biomarkers
Language	English
Publishing date	2023-02-11
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1212497-7
ISSN	1365-2893 ; 1352-0504
ISSN (online)	1365-2893
ISSN	1352-0504
DOI	10.1111/jvh.13808
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4119: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito